MERLIN INC

Merlin Inc. stock dives 48%—investors wary as the firm plans a late Q3 webcast amid steep price collapse and unfulfilled autonomy promises.

Merlin (MRLN) drops 6.7% to $0.93, trailing a 48.96% monthly decline and far below its 200‑day MA—while peers like Outlook Therapeutics climb 7.9%.

Merlin’s shares slip 1.87 % amid a 43.55 % monthly decline—under‑$1 stock, outpaced by peers, yet still a potential high‑beta entry if a catalyst arrives.